Lantern Pharma Advocates AI-Driven Approach to Address 'Broken' Biotech Model at Industry Summit

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company based in Dallas, was featured in a Dallas Innovates article covering the 2025 BioNTX iC3 Summit, where industry leaders declared the traditional biotech model broken. CEO Panna Sharma, who served as both moderator and panelist at the event, highlighted the urgent need for technological adoption in drug development. Sharma stated, "The process of actually making drugs is still largely manual. We have the technology to change that, but the industry hasn’t adopted it fast enough." This sentiment echoes the summit's broader call for innovation to address inefficiencies in biotech.

The article underscored Sharma's perspective that AI-driven platforms like Lantern Pharma's RADR can revolutionize oncology drug development by streamlining discovery processes, accelerating clinical timelines, and reducing costs. By leveraging over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms, RADR aims to solve significant challenges in drug development. The full details of the summit discussions are available in the original article at https://ibn.fm/DM9ur. This approach positions Lantern Pharma at the forefront of efforts to create a more sustainable and efficient future for the biotech industry, directly responding to the summit's emphasis on data-driven solutions.

Lantern Pharma's initiatives are part of a growing movement to transform the cost, pace, and timeline of oncology drug discovery. The company's pipeline includes a Phase 2 clinical program and multiple Phase 1 trials, with potential therapies spanning solid tumors, blood cancers, and an antibody-drug conjugate program. These efforts are estimated to have a combined annual market potential of over $15 billion, underscoring the economic implications of adopting AI in biotech. For ongoing updates, the company maintains a newsroom at https://ibn.fm/LTRN. The broader industry shift toward AI, as championed by Lantern Pharma, could lead to more accessible and life-changing therapies for cancer patients worldwide, marking a critical step in fixing the broken biotech model.